The alveolar macrophage: The forgotten cell in asthma

American Journal of Respiratory Cell and Molecular Biology

Volumn 31, Issue 1, 2004, Pages 3-7

  Peters Golden, Marc ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 6301 MSRB III ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; CARBON MONOXIDE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 5; LIPOXIN A; NITRIC OXIDE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BRONCHODILATATION; BRONCHOSPASM; CELL DEATH; CELL FUNCTION; CELL INTERACTION; CELL TYPE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; EOSINOPHIL; EPITHELIUM CELL; FIBROBLAST; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MAST CELL; MUSCLE CONTRACTILITY; NONHUMAN; OXYGENATION; PATHOGENESIS; PHAGOCYTOSIS; REVIEW; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; ASTHMA; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MACROPHAGES, ALVEOLAR; RATS; SPECIES SPECIFICITY;

EID: 3042838551     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.f279     Document Type: Review

References (58)

1. Busse, W. W., and R. F. Lemanske, Jr. 2001. Asthma. N. Engl. J. Med. 344:350-362.
2. Hocking, W., and D. Golde. 1979. The pulmonary alveolar macrophage. N. Engl. J. Med. 301:580-587, 639-644.
3. Lohmann-Matthes, M., C. Steinmuller, and G. Franke-Ullmann. 1994. Pulmonary macrophages. Eur. Respir. J. 7:1678-1689.
4. Eissa, N., and D. Huston. editors. 2003. Therapeutic Targets in Airway Inflammation. Marcel Dekker, Inc., New York.
5. Daser, A., M. Daheshia, and G. T. De Sanctis. 2001. Genetics of allergen-induced asthma. J. Allergy Clin. Immunol. 108:167-174.
6. Wills-Karp, M., and S. L. Ewart. 1997. The genetics of allergen-induced airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 156:S89-S96.
7. Careau, E., and E. Y. Bissonnette. 2004. Adoptive transfer of alveolar macrophages abrogates bronchial hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 31:22-27.
8. Myrvik, Q., E. S. Leake, and B. Fariss. 1961. Studies on pulmonary alveolar macrophages from the normal rabbit: a technique to procure them in a high state of purity. J. Immunol. 86:128-132.
9. Finley, T. N., E. W. Swenson, W. S. Curran, G. L. Huber, and A. J. Ladman. 1967. Bronchopulmonary lavage in normal subjects and patients with obstructive lung disease. Ann. Intern. Med. 66:651-658.
10. van Rooijen, N., and R. van Nieuwmegen. 1984. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate: an enzyme-histochemical study. Cell Tissue Res. 238:355-358.
11. Thepen, T., N. Van Rooijen, and G. Kraal. 1989. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J. Exp. Med. 170:499-509.
12. Wu, M., S. Hussain, Y. H. He, R. Pasula, P. A. Smith, and W. J. Martin, II. 2001. Genetically engineered macrophages expressing IFN-gamma restore alveolar immune function in seid mice. Proc. Natl. Acad. Sci. USA 98:14589-14594.
13. Kradin, R. L., H. W. Liu, N. van Rooijen, K. Springer, L. H. Zhao, and C. P. Leary. 1999. Pulmonary immunity to Listeria is enhanced by elimination of alveolar macrophages. Am. J. Respir. Crit. Care Med. 159:1967-1974.
14. Pasula, R., T. Weaver, M. A. Martinez, and W. J. Martin, II. 2002. Morphologic detection and functional assessment of reconstituted normal alveolar macrophages in the lungs of SCID mice. J. Immunol. 169:4504-4510.
15. Broug-Holub, E., G. B. Toews, J. F. van Iwaarden, R. M. Strieter, S. L. Kunkel, R. Paine, III, and T. J. Standiford. 1997. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect. Immun. 65:1139-1146.
16. Holt, P. G., J. Oliver, N. Bilyk, C. McMenamin, P. G. McMenamin, G. Kraal, and T. Thepen. 1993. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J. Exp. Med. 177:397-407.
17. Thepen, T., C. McMenamin, J. Oliver, G. Kraal, and P. G. Holt. 1991. Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity. Eur. J. Immunol. 21:2845-2850.
18. Tang, C., M. D. Inman, N. van Rooijen, P. Yang, H. Shen, K. Matsumoto, and P. M. O'Byrne. 2001. Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-gamma-dependent mechanism. J. Immunol. 166:1471-1481.
19. Singh, P., M. Daniels, D. W. Winsett, J. Richards, D. Doerfler, G. Hatch, K. B. Adler, and M. I. Gilmour. 2003. Phenotypic comparison of allergic airway responses to house dust mite in three rat strains. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:L588-L598.
20. Hylkema, M. N., M. O. Hoekstra, M. Luinge, and W. Timens. 2002. The strength of the OVA-induced airway inflammation in rats is strain dependent. Clin. Exp. Immunol. 129:390-396.
21. Plummeridge, M. J., L. Armstrong, M. A. Birchall, and A. B. Millar. 2000. Reduced production of interleukin 12 by interferon gamma primed alveolar macrophages from atopic asthmatic subjects. Thorax 55:842-847.
22. Ho, L. P., M. Davis, A. Denison, F. T. Wood, and A. P. Greening. 2002. Reduced interleukin-18 levels in BAL specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects. Chest 121:1421-1426.
23. Sirois, J., and E. Y. Bissonnette. 2001. Alveolar macrophages of allergic resistant and susceptible strains of rats show distinct cytokine profiles. Clin. Exp. Immunol. 126:9-15.
24. Mills, C. D., K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164:6166-6173.
25. Jesch, N. K., M. Dorger, K. Messmer, and F. Krombach, 1998. Formation of nitric oxide by rat and hamster alveolar macrophages: an interstrain and interspecies comparison. Toxicol. Lett. 96-97:47-51.
26. Kay, A. B. 2003. Immunomodulation in asthma: mechanisms and possible pitfalls. Curr. Opin. Pharmacol. 3:220-226.
27. Gaston, B., J. M. Drazen, J. Loscalzo, and J. S. Stamler. 1994. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med. 149:538-551.
28. Xiong, Y., G. Karupiah, S. P. Hogan, P. S. Foster, and A. J. Ramsay. 1999. Inhibition of allergic airway inflammation in mice lacking nitric oxide synthase 2. J. Immunol. 162:445-452.
29. Liew, F. Y. 1995. Regulation of lymphocyte functions by nitric oxide. Curr. Opin. Immunol. 7:396-399.
30. Kharitonov, S. A., D. H. Yates, and P. J. Barnes. 1996. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am. J. Respir. Crit. Care Med. 153:454-457.
31. Silkoff, P. E., P. A. McClean, A. S. Slutsky, M. Caramori, K. R. Chapman, C. Gutierrez, and N. Zamel. 1998. Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma. J. Asthma 35:473-479.
32. Coffey, M., S. Phare, and M. Peters-Golden. 2000. Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J. Immunol. 165:3592-3598.
33. Thomassen, M. J., L. T. Buhrow, M. J. Connors, F. T. Kaneko, S. C. Erzurum, and M. S. Kavuru. 1997. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 17:279-283.
34. Raychaudhuri, B., R. Dweik, M. J. Connors, L. Buhrow, A. Malur, J. Drazba, A. C. Arroliga, S. C. Erzurum, M. S. Kavuru, and M. J. Thomassen. 1999. Nitric oxide blocks nuclear factor-kappaB activation in alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 21:311-316.
35. Kacmarek, R. M., R. Ripple, B. A. Cockrill, K. J. Bloch, W. M. Zapol, and D. C. Johnson. 1996. Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm. Am. J. Respir. Crit. Care Med. 153:128-135.
36. Fang, F. C., and A. Vazquez-Torres. 2002. Nitric oxide production by human macrophages: there's NO doubt about it. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:L941-L943.
37. Chapman, J. T., L. E. Otterbein, J. A. Elias, and A. M. Choi. 2001. Carbon monoxide attenuates aeroallergen-induced inflammation in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 281:L209-L216.
38. Harju, T., Y. Soini, R. Paakko, and V. L. Kinnula. 2002. Up-regulation of heme oxygenase-I in alveolar macrophages of newly diagnosed asthmatics. Respir. Med. 96:418-423.
39. Pavord, I., R. Ward, G. Woltmann, A. Wardlaw, J. Sheller, and R. Dworski. 1999. Induced sputum eicosanoid concentrations in asthma. Am. J. Respir. Crit. Care Med. 160:1905-1909.
40. 2 and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J. Allergy Clin. Immunol. 104:153-162.
41. 2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia. J. Allergy Clin. Immunol. 112:709-716.
42. 2 on allergen-induced asthma. Am. Rev. Respir. Dis. 148:87-90.
43. 2. Lancet 345:436-438.
44. 4 release from activated neutrophils. Proc. Natl. Acad. Sci. USA 80:4349-4353.
45. 2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263:5380-5384.
46. Belvisi, M., M. Saunders, M. Yacoub, and J. Mitchell. 1998. Expression of cyclooxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth. Br. J. Pharmacol. 125:1102-1108.
47. 2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29:537-544.
48. 2. Trends Immunol. 25:40-46.
49. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146:108-113.
50. Lai, C. K., G. D. Phillips, J. R. Jenkins, and S. T. Holgate. 1990. The effect of inhaled 15-(s)-hydroxyeicosatetraenoic acid (15-HETE) on airway calibre and non-specific responsiveness in normal and asthmatic human subjects. Eur. Respir. J. 3:38-45.
51. Chang, J., B. Lamb, L. Marinari, A. Kreft, and A. Lewis. 1985. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages. Eur. J. Pharmacol. 107:215-222.
52. Mueller, C., V. Weaver, J. P. Vanden Heuvel, A. August, and M. T. Cantorna. 2003. Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch. Biochem. Biophys. 418:186-196.
53. Wang, A., X. Dai, B. Luu, and D. Conrad. 2001. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am. J. Respir. Cell Mol. Biol. 24:688-693.
54. Bell-Parikh, L. C., T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald. 2003. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 112:945-955.
55. 4. Nat. Med. 8:931-932.
56. Levy, B. D., M. Romano, H. A. Chapman, J. J. Reilly, J. Drazen, and C. N. Serhan. 1993. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 92:1572-1579.
57. Fadok, V. A., D. L. Bratton, A. Konowal, P. W. Freed, J. Y. Westcott, and P. M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta. PGE2, and PAF. J. Clin. Invest. 101:890-898.
58. Alexis, N. E., J. Soukup, S. Nierkens, and S. Becker. 2001. Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:L369-L375.